A carregar...
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are “addicted” to its continued function. Now, crizotinib, an oral ALK inhibitor, is demons...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3110762/ https://ncbi.nlm.nih.gov/pubmed/21156280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2010.11.033 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|